A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates.
Hepatic encephalopathy
Hospital readmission
Hospitalization
Inpatient mortality
Medical education
Quality improvement
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
received:
31
08
2023
accepted:
09
04
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
23
4
2024
Statut:
aheadofprint
Résumé
Over 50% of hospitalizations from hepatic encephalopathy (HE) are preventable, but patients often do not receive medical treatment. To use a multimodal education intervention (MMEI) to increase HE treatment rates and to evaluate (1) trends in HE treatment, (2) predictors of receiving treatment, and (3) the impact of treatment on hospitalization outcomes. Prospective single-center cohort study of patients hospitalized with HE from April 1, 2020-September 30, 2022. The first 15 months were a control ("pre-MMEI"), the subsequent 15 months (MMEI) included three phases: (1) prior authorization resources, (2) electronic order set, and (3) in-person provider education. Treatment included receiving any drug (lactulose or rifaximin), or combination therapy. Treatment rates pre- vs. post-MMEI were compared using logistic regression. 471 patients were included. There were lower odds of receiving any drug post-MMEI (p = 0.03). There was no difference in receiving combination therapy pre- or post-MMEI (p = 0.32). Predictors of receiving any drug included alcohol-related or cryptogenic cirrhosis (p's < 0.001), and the presence of ascites (p = 0.005) and/or portal hypertension (p = 0.003). The only significant predictor of not receiving any drug treatment was having autoimmune cirrhosis (p < 0.001). Patients seen by internal medicine (p = 0.01) or who were intoxicated (p = 0.02) were less likely to receive rifaximin. Any treatment was associated with higher 30-day liver disease-specific readmission (p < 0.001). This MMEI did not increase HE treatment rates, suggesting that alternative strategies are needed to identify and address barriers to treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Over 50% of hospitalizations from hepatic encephalopathy (HE) are preventable, but patients often do not receive medical treatment.
AIMS
OBJECTIVE
To use a multimodal education intervention (MMEI) to increase HE treatment rates and to evaluate (1) trends in HE treatment, (2) predictors of receiving treatment, and (3) the impact of treatment on hospitalization outcomes.
METHODS
METHODS
Prospective single-center cohort study of patients hospitalized with HE from April 1, 2020-September 30, 2022. The first 15 months were a control ("pre-MMEI"), the subsequent 15 months (MMEI) included three phases: (1) prior authorization resources, (2) electronic order set, and (3) in-person provider education. Treatment included receiving any drug (lactulose or rifaximin), or combination therapy. Treatment rates pre- vs. post-MMEI were compared using logistic regression.
RESULTS
RESULTS
471 patients were included. There were lower odds of receiving any drug post-MMEI (p = 0.03). There was no difference in receiving combination therapy pre- or post-MMEI (p = 0.32). Predictors of receiving any drug included alcohol-related or cryptogenic cirrhosis (p's < 0.001), and the presence of ascites (p = 0.005) and/or portal hypertension (p = 0.003). The only significant predictor of not receiving any drug treatment was having autoimmune cirrhosis (p < 0.001). Patients seen by internal medicine (p = 0.01) or who were intoxicated (p = 0.02) were less likely to receive rifaximin. Any treatment was associated with higher 30-day liver disease-specific readmission (p < 0.001).
CONCLUSION
CONCLUSIONS
This MMEI did not increase HE treatment rates, suggesting that alternative strategies are needed to identify and address barriers to treatment.
Identifiants
pubmed: 38652390
doi: 10.1007/s10620-024-08445-2
pii: 10.1007/s10620-024-08445-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716–721.
pubmed: 11870389
doi: 10.1053/jhep.2002.31250
Vilstrup H, Amodio P, Bajaj J et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715–735.
pubmed: 25042402
doi: 10.1002/hep.27210
American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease. practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014;2014:642–659.
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol 2022;77:807–824.
doi: 10.1016/j.jhep.2022.06.001
Bajaj JS, O’Leary JG, Tandon P et al. Hepatic encephalopathy is associated with mortality in patients with cirrhosis independent of other extrahepatic organ failures. Clin Gastroenterol Hepatol 2017;15:565–574.
pubmed: 27720916
doi: 10.1016/j.cgh.2016.09.157
Patidar KR, Thacker LR, Wade JB et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014;109:1757.
pubmed: 25178701
pmcid: 4321782
doi: 10.1038/ajg.2014.264
Tapper EB, Aberasturi D, Zhao Z et al. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther. 2020;51:1397–1405.
pubmed: 32363684
pmcid: 7266029
doi: 10.1111/apt.15749
Moon AM, Kim HP, Jiang Y et al. Systematic review and meta-analysis on the effects of lactulose and Rifaximin on patient-reported outcomes in hepatic encephalopathy. Am J Gastroenterol. 2023;118:284–293.
pubmed: 36730910
doi: 10.14309/ajg.0000000000002008
Bajaj JS, Saeian K, Schubert CM et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175–1183.
pubmed: 19670416
doi: 10.1002/hep.23128
Gluud LL, Jeyaraj R, Morgan MY. Outcomes in clinical trials evaluating interventions for the prevention and treatment of hepatic encephalopathy. J Clin Exp Hepatol 2019;9:354–361.
pubmed: 31360028
pmcid: 6637116
doi: 10.1016/j.jceh.2019.02.004
Tapper EB, Henderson JB, Parikh ND et al. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans With cirrhosis. Hepatol Commun. 2019;3:1510–1519.
pubmed: 31701074
pmcid: 6824059
doi: 10.1002/hep4.1425
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–231.
pubmed: 16298014
doi: 10.1016/j.jhep.2005.10.013
Bajaj JS, Lauridsen M, Tapper EB et al. Important unresolved questions in the management of hepatic encephalopathy: An ISHEN consensus. Am J Gastroenterol 2020;115:989–1002.
pubmed: 32618647
doi: 10.14309/ajg.0000000000000603
Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012;55:1164–1171.
pubmed: 22135042
doi: 10.1002/hep.25507
Bajaj JS, Sanyal AJ, Bell D et al. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010;31:1012–1017.
pubmed: 20136802
doi: 10.1111/j.1365-2036.2010.04257.x
Zeng Z, Li YY, Jia L et al. Influence of lactulose on the cognitive level and quality of life in patients with minimal hepatic encephalopathy. Chin J Clin Rehabil 2006;10:165–167.
Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071–1081.
pubmed: 20335583
doi: 10.1056/NEJMoa0907893
Ali B, Zaidi YA, Alam A, Anjum HA. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. J Coll Physicians Surg Pak 2014;24:269–273.
pubmed: 24709242
Kimer A, Krag A, Møller S et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123–132.
pubmed: 24849268
doi: 10.1111/apt.12803
Sanyal A, Younossi ZM, Bass NM et al. Randomised clinical trial: Rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy—a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;34:853–861.
pubmed: 21848797
doi: 10.1111/j.1365-2036.2011.04808.x
Sidhu SS, Goyal O, Parker RA et al. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int 2016;36:378–85.
pubmed: 26201713
doi: 10.1111/liv.12921
Kimer N, Krag A, Moller S et al. Systematic review with meta-analysis: The effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123–132.
pubmed: 24849268
doi: 10.1111/apt.12803
Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016;43:11–26.
pubmed: 26618922
doi: 10.1111/apt.13435
Prasad S, Dhiman RK, Duseja A et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549–559.
pubmed: 17326150
doi: 10.1002/hep.21533
Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Ther Adv Gastroenterol. 2011;4:199–206.
doi: 10.1177/1756283X11401774
Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol 2019;31:434–450.
pubmed: 30444745
doi: 10.1097/MEG.0000000000001311
Dhiman RK, Thumburu KK, Verma N et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2020;18:800–812.
pubmed: 31476436
doi: 10.1016/j.cgh.2019.08.047
Wang Z, Chu P, Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther 2018;13:1–11.
pubmed: 30587923
pmcid: 6301297
doi: 10.2147/DDDT.S172324
Sharma BC, Sharma P, Lunia MK et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013;108:1458–1463.
pubmed: 23877348
doi: 10.1038/ajg.2013.219
Fu J, Gao Y, Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis. PLoS ONE 2022;17:e0267647.
pubmed: 35471992
pmcid: 9041837
doi: 10.1371/journal.pone.0267647
Sanyal AJ, Heimanson Z, Israel R, et al. Prevention of overt hepatic encephalopathy recurrence with rifaximin alone versus rifaximin plus lactulose therapy: Impact on quality of life and caregiver burden in patients with cirrhosis. Presented at Hospital Medicine April 8–11, 2018, Orlando, FL, 2018.
Bajaj JS, Heuman DM, Wade JB et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011;140:478–487.
pubmed: 20849805
doi: 10.1053/j.gastro.2010.08.061
Rahim MN, Miquel R, Heneghan MA. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep 2020;2:100149.
pubmed: 32995712
pmcid: 7509236
doi: 10.1016/j.jhepr.2020.100149
Taylor MJ, McNicholas C, Nicolay C et al. Systematic review of the application of the plan-do-study-act method to improve quality in healthcare. BMJ Qual Saf. 2014;23:290–298.
pubmed: 24025320
doi: 10.1136/bmjqs-2013-001862
Kobsa A. Personalized hypermedia systems may be in conflict with privacy concerns of computer. Commun ACM 2002;45:64–67.
doi: 10.1145/506218.506249
Lampe C, Wohn DY, Vitak J et al. Student use of Facebook for organizing collaborative classroom activities. Int J Comput Support Collab Learn 2011;6:329–347.
doi: 10.1007/s11412-011-9115-y
Garett R, Chiu J, Zhang L, Young SD. A literature review: website design and user engagement. Online J Commun Media Technol. 2016;6:1–14.
pubmed: 27499833
pmcid: 4974011
doi: 10.29333/ojcmt/2556
Constantiou I, Kallinikos J. (2015). New games, new rules: big data and the changing context of strategy, LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library.
Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39:II46-54.
pubmed: 11583121
doi: 10.1097/00005650-200108002-00003
Sittig DF, Wright A, Osheroff JA et al. Grand challenges in clinical decision support. J Biomed Inform. 2008;41:387–392.
pubmed: 18029232
doi: 10.1016/j.jbi.2007.09.003
Fontaine P, Ross SE, Zink T, Schilling LM. Systematic review of health information exchange in primary care practices. J Am Board Fam Med 2010;23:655–670.
pubmed: 20823361
doi: 10.3122/jabfm.2010.05.090192
Carroll C, Patterson M, Wood S et al. A conceptual framework for implementation fidelity. Implementation Sci 2007;2:40.
doi: 10.1186/1748-5908-2-40
Prince M. Does active learning work? A review of the research. Journal of Engineering Education 2004;93:223–231.
doi: 10.1002/j.2168-9830.2004.tb00809.x
Thistlethwaite JE, Davies D, Ekeocha S, et al. The effectiveness of case-based learning in health professional education. A BEME systematic review: BEME Guide No. 23. Med Teach. 2012;34:e421–44.
Marinopoulos SS, Dorman T, Ratanawongsa N, et al. Effectiveness of continuing medical education. Evid Rep Technol Assess (Full Rep). 2007:1–69.
Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700–5.
pubmed: 7650822
doi: 10.1001/jama.1995.03530090032018